Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers†

8 Oct 2009

Abstract excerpt

AIMS: The cardiomyopathy found in Duchenne muscular dystrophy (DMD) is responsible for death due to heart failure in approximately 30% of patients and additionally contributes to many DMD morbidities. Strategies to bypass DMD-causing mutations to allow an increase in body-wide dystrophin have proved promising, but increasing cardiac dystrophin continues to be challenging. The purpose of this study was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Mesenchymal stem cell research
Share to Muscle Physiology and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19815563
DOI: 10.1093/cvr/cvp335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers†PMID 19815563Read ↗

Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomerSemantic proximity Read ↗

Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMOSemantic proximity Read ↗

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.Semantic proximity Read ↗

Long-Term Systemic Administration of Unconjugated Morpholino Oligomers for Therapeutic Expression of Dystrophin by Exon Skipping in Skeletal Muscle: Implications for Cardiac Muscle IntegritySemantic proximity Read ↗

RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models.Semantic proximity Read ↗

Timing matters: exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophySemantic proximity Read ↗

Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse modelSemantic proximity Read ↗

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseasesSemantic proximity Read ↗

Next steps for the optimization of exon therapy for Duchenne muscular dystrophySemantic proximity Read ↗

In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52–Deficient mdx MouseSemantic proximity Read ↗

PPMO-mediated exon skipping induces uniform sarcolemmal dystrophin rescue with dose-dependent restoration of circulating microRNA biomarkers and muscle biophysical propertiesSemantic proximity Read ↗

Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.